Peptide News Digest

#Duravelo-2

2 stories

Clinical Trials · View digest

Bicycle Therapeutics Duravelo-2 Oral Abstract Confirmed for ASCO 2026 June 1 (8:30 a.m. CT): Zelenectide Pevedotin (BT8009) + Pembrolizumab Interim Analysis in 1L Locally Advanced/Metastatic Urothelial Cancer

Bicycle Therapeutics confirmed the Duravelo-2 oral abstract presentation slot at the ASCO 2026 Annual Meeting on Monday, June 1, 8:30–8:36 a.m. CT. The abstract reports interim analysis results from Duravelo-2, a Phase 2/3 trial of zelenectide pevedotin (BT8009) plus pembrolizumab as first-line treatment for previously untreated locally advanced or metastatic urothelial carcinoma. Zelenectide pevedotin is Bicycle's Nectin-4-targeting bicyclic peptide-drug conjugate, a separate program from the EphA2-targeting nuzefatide pevedotin (BT5528) covered earlier on this site. The Q1 2026 print (April 30) reaffirmed $559.5M cash and runway to 2030 supporting the Phase 3 expansion of the platform.

Industry · View digest

Bicycle Therapeutics Q1 2026 (April 30): $559.5M Cash, Cash Runway to 2030, $60.8M Net Loss; Nuzefatide Pevedotin Duravelo-2 Dose-Selection Heading to ASCO 2026

Bicycle Therapeutics reported Q1 2026 financial results April 30 — net loss of $60.8M ($0.87 per share) on R&D of approximately $44M, with $559.5M in cash and equivalents at March 31 supporting a cash runway into 2030. The pipeline update reaffirmed that nuzefatide pevedotin (BT5528) Duravelo-2 dose-selection data in EphA2-positive solid tumors will be presented at the ASCO 2026 Rapid Oral Abstract Session on June 1, the Phase 2 nuzefatide pevedotin trial in recurrent pancreatic cancer enrolled its first patient in April, and the EphA2 gallium-68 PET imaging program continues to accumulate first-in-human data. Bicycle remains the leading bicyclic-peptide-platform pure-play in oncology.